Skip to content


We are advancing a pipeline of antibody-based precision radiotherapeutics based on our proprietary ROVErâ„¢ platform to tackle a variety of cancer indications with high unmet need.

Each program utilizes a ROVErâ„¢ platform antibody that binds a solid tumor target and is designed to optimize therapeutic index of therapeutic radioisotopes. Our approach also allows a corresponding imaging agent to be employed to assess healthy tissue exposure (dosimetry), measure target engagement, select the right patients and guide clinical development.


Lead Optimization
Phase 1
ABD-147 SCLC and LCNEC ABD-147
Phase: Phase 1
ABD-002 Undisclosed Target ABD-002
ABD-002 Undisclosed Target
Phase: IND-Enabling
ABD-003 Undisclosed Target ABD-003
ABD-003 Undisclosed Target
Phase: Lead Optimization
ABD-004 Undisclosed Target ABD-004
ABD-004 Undisclosed Target
Phase: Lead Optimization
ABD-005 Undisclosed Target ABD-005
ABD-005 Undisclosed Target
Phase: Discovery
ABD-006 Undisclosed Target ABD-006
ABD-006 Undisclosed Target
Phase: Discovery
Phase: Discovery

ABD-147 for Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma

ABD-147 is a next-generation precision radiopharmaceutical biologic therapy designed to deliver Actinium-225 (225Ac), a highly potent alpha-emitting radioisotope, to solid tumors expressing delta-like ligand 3 (DLL3).

DLL3 is a protein in the Notch pathway that is critical for the development and regulation of neuroendocrine versus epithelial cell differentiation in the lungs. In certain high grade neuroendocrine carcinomas including small cell lung cancer (SCLC), DLL3 is upregulated and specifically expressed on the cell surface. In contrast, DLL3 is absent or very rarely expressed on the surface of nonmalignant cells. Given the high specificity of DLL3 expression on cancer cells and the distinct mechanism of action, DLL3 represents a compelling target for treating SCLC and other DLL3+ solid tumors with targeted radiotherapy.

Abdera plans to initiate a Phase 1 clinical of ABD-147 in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) later this year.


The global incidence for SCLC and LCNEC has been reported to represent approximately 325,000 patients and is expected to grow 4% annually through 2029. In the U.S., the incidence has been reported to be approximately 35,000 new cases annually. These cancers have the most aggressive clinical course of any type of pulmonary tumor. These tumors often metastasize to other parts of the body, including the brain, liver and bone. Without treatment, the median survival from diagnosis has been reported to be only two to four months. With treatment, the overall survival at five years is 5% to 10% for SCLC, and 15% to 25% for LCNEC. SCLC and LCNEC generally carry a poor prognosis and new treatment options are urgently needed.